Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Trill Impact in connection with the acquisition of ID North AB
Mandate

Vinge advises Trill Impact in connection with the acquisition of ID North AB

October 25, 2021 Corporate Commercial IT, Telecommunications and Outsourcing Intellectual Property M&A

Vinge advises Trill Impact in connection with the acquisition of ID North AB (”ID North”).

ID North operates within Identity Access Management and cyber security providing IT consulting services, resale and in-house development of IT products with its base in Stockholm. With an ambition to build a leading group that addresses the increasing need for cybersecurity services, the acquisition of ID North comprises one of two platform investments to the new group called European ID Security.

Vinge’s team consisted of Christina Kokko together with Karl Klackenberg, Desirée Hagenfeldt and Nina Gransäter (M&A), Åsa Gotthardsson and Carl Östlund (Employment), Sofia Bergenstråhle (IP), Alva Hägglund (Corporate Commercial), Karl-Hugo Engdahl (IT and GDPR), Tove Lövgren Frisk (Compliance) and Sara Dahlros Sköld (VDR assistant).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025